Our People

Caring

Work that is Personal

Because we work with people who are living with type 1 diabetes, our mission is personal. That connection helps fuel our passion and drives our commitment to serving the diabetes community.

Brittney, diagnosed 2008
Annie, diagnosed 2011
Blair, diagnosed 2000
Casual

Life at Tandem

Though we take our work extremely seriously, we remain true to our casual, uplifting, and innovative roots.

Explore Culture

Checkmark List

Words We Live By

We're creating new possibilities for people living with diabetes, their loved ones, and their healthcare providers.

Learn More
Briefcase

Work with Us

Put your passion behind our pumps. Search positions, create or update your profile, and apply for a position!

Apply Today

Tom, Chief Scientist

Tandem Spotlight People Behind the Pump

The roots of our Tandem Family are strong — whether it’s a Tandem Diabetes Care employee or someone who relies on us to help better manage their diabetes. Meet some of the people behind the pump.

Briefcase

Executive Team

John Sheridan

President and Chief Executive Officer

Mr. Sheridan has served on our board of directors since June 2019 and as our President and Chief Executive Officer since March 2019. Prior to that, Mr. Sheridan served as our Executive Vice President and Chief Operating Officer since April 2013. Prior to joining us, Mr. Sheridan served as Chief Operating Officer of Rapiscan Systems, Inc., a provider of security equipment and systems, from March 2012 to February 2013. Mr. Sheridan served as Executive Vice President of Research and Development and Operations for Volcano Corporation, a medical technology company, from November 2004 to March 2010. From May 2002 to May 2004, Mr. Sheridan served as Executive Vice President of Operations at CardioNet, Inc., a medical technology company, now operating as BioTelemetry, Inc. (Nasdaq: BEAT). From March 1998 to May 2002, he served as Vice President of Operations at Digirad Corporation, a medical imaging company. Mr. Sheridan serves as a director of Acutus Medical, Inc. (Nasdaq: AFIB), an arrhythmia management company. Mr. Sheridan holds a BS in Chemistry from the University of West Florida and an MBA from Boston University.

David Berger

Executive Vice President And Chief Operating Officer

David Berger has served as our Executive Vice President and Chief Operating Officer since February 2022 and is responsible for the Company’s manufacturing, supply chain, quality, regulatory and clinical functions.  He previously served as our Chief Business Operations and Compliance Officer since November 2020, as our Executive Vice President, Chief Legal and Compliance Officer since April 2019, and as General Counsel since August 2013.  From January 2008 until August 2013, Mr. Berger was employed at Senomyx, Inc., a taste science company, where he most recently served as Senior Vice President and General Counsel.  From April 2003 until October 2007, Mr. Berger was responsible for all commercial aspects of legal affairs at Biosite Incorporated, Biosite, a provider of medical diagnostic products, most recently serving as Vice President, Legal Affairs. Previously, Mr. Berger was an attorney at Cooley Godward LLP and Amylin Pharmaceuticals, Inc. Mr. Berger holds a BA in Economics from the University of California, Berkeley and a JD from Stanford Law School.

Rick Carpenter

Chief Technical Officer

Rick Carpenter has served as our Chief Technical Officer since November 2021. Prior to joining our company, Mr. Carpenter served from February 2020 as the Senior Vice President of Engineering at Inseego Corporation, where he led the worldwide engineering team and was responsible for device hardware and software, cloud software, quality assurance, regulatory and product certification and technical account management. From April 2017 to January 2020, he was the General Manager of the IoMT Business and the Senior Director of Engineering at Capsule Technologies, a company that integrates medical devices and wearables into a secure medical grade system that collects data and provides it to healthcare professionals for patient monitoring. Prior to that, from May 2009 until March 2017, Mr. Carpenter served as the Senior Vice President of Engineering at Smith Micro Software. Earlier in his career, he held various engineering development and leadership roles at Nextwave Wireless, Sierra Wireless, General Dynamics, Motorola and Denso. Mr. Carpenter received a BS in Computer Science from The University of Texas Permian Basin, and completed coursework for an MS in Computer Science from The University of Texas at Arlington.

Tom Fox

Chief Human Resources Officer

Tom Fox was appointed Chief Human Resources Officer in August 2023. From August 2020 to July 2023, he served as Senior Vice President, Human Resources and Organizational Development. From August 2017 to July 2020, he served as Vice President, Human Resources. Prior to this, he served as Senior Director of our Human Resources Department. Mr. Fox has more than 20 years of experience in Human Resources management. Prior to joining Tandem, Mr. Fox served as Director of Human Resources for the Oncology-Genoptix Division of Novartis Pharmaceuticals. Before that, he held various HR leadership positions including Director of Human Resources for the West Division of BDO, USA LLP; Director of HR Client Services for Option One Mortgage Company (a subsidiary of H&R Block Corp.) and Director of Labor and Employee Relations at The Walt Disney Company, Disneyland Resort. Mr. Fox began his career at Chevron Corporation and holds a BS in Business Administration from California State University, Fresno and a MS in Labor Relations and Human Resources Management from Michigan State University.

Elizabeth Gasser

Executive Vice President and Chief Strategy and Product Officer

Elizabeth Gasser has served as our Executive Vice President and Chief Strategy and Product Officer since November 2023. From June 2021 to November 2023, Ms. Gasser served as Executive Vice President and Chief Strategy Officer. From January 2020 to June 2021, she served as Executive Vice President, Strategy and Corporate Development. Prior to joining our Company, Ms. Gasser served from June 2017 as an independent adviser providing strategic and corporate development solutions to boards and executive teams. From January 2016 to June 2017, she was Vice President of Corporate Strategy at QUALCOMM Technologies, Inc. (QTI), a subsidiary of QUALCOMM Incorporated (Nasdaq: QCOM), a global leader in the development and commercialization of technologies and products used in mobile devices and other wireless products. Prior to that, from November 2012 to January 2016, she was Vice President of Strategic Development at QTI, after serving in other strategic-related roles of increasing responsibility beginning in 2006. Ms. Gasser holds a BA and an MA in Economics from the University of Cambridge.

Brian Hansen

Executive Vice President and Chief Commercial Officer (Exiting)

Brian Hansen has served as our Executive Vice President and Chief Commercial Officer since February 2016. Prior to joining our Company, Mr. Hansen served from September 2014 as Chief Commercial Officer of Adaptive Biotechnologies Corp. From May 2013 to September 2014, Mr. Hansen served as Head of Commercial, Sales and Marketing, of Genoptix, a Novartis Company. From December 2005 to February 2013, he served in various roles of increasing responsibility at Gen-Probe, Inc., a medical diagnostics company, most recently serving as Senior Vice President, Global Sales and Services from January 2012 to February 2013. Mr. Hansen received a BS in Business Administration from the University of Missouri-Columbia and an MBA from the School of Business at San Diego State University.

Jim Leal

Chief Manufacturing Officer

Jim Leal was appointed Chief Manufacturing Officer in April 2023. From August 2017 to April 2023, he served as Senior Vice President, Operations.  Prior to this, he served as Vice President, Operations. Mr. Leal has more than 25 years of manufacturing and engineering experience. Prior to joining Tandem, Mr. Leal was the Vice President of Manufacturing and Field Support for Volcano Corporation and held Director Roles with CardioNet, Inc. and Digirad Corporation. He held Senior Engineering roles with FlipChip Technologies and Hughes Aircraft Company. Jim has won several awards including a Hughes Aircraft Doctoral and Masters Fellowship and was a recognized nominee for Most Promising Hispanic Engineer of the Year Award. Mr. Leal is a published author and patent holder. He is a University of Arizona graduate with a PhD in Materials Science and Engineering.

Huzefa Neemuchwala

Senior Vice President, Product Management

Huzefa Neemuchwala joined us as Senior Vice President, Product Management in November 2021. Prior to joining Tandem, Dr. Neemuchwala served as Vice President, Digital Transformation at Johnson & Jonson MedTech’s Robotics and Digital Surgery Solutions unit. At Johnson & Johnson, he also served as CEO of portfolio company, C-SATS Inc. and VP, Global Education Solutions. Prior to Johnson & Johnson, he was Global Head, Digital Health Solutions and AI at Medtronic Diabetes, and an Innovation leader at Abbott Diabetes Care. Prior to that, Huzefa worked at Hologic and Fujifilm Medical Systems in roles that developed and commercialized AI/ML solutions in Radiology for breast cancer. Dr. Neemuchwala holds a BS in Biomedical Engineering from the University of Mumbai, India.  He also holds a MS in Electrical Engineering and Computer Sciences from the University of Michigan and a MS in Biomedical Engineering from the University of Texas Southwestern Medical School.  Dr. Neemuchwala holds a MBA from University of California Berkeley - Haas and a PhD in Biomedical Engineering from the University of Michigan at Ann Arbor.

Mark Novara

Executive Vice President and Chief Commercial Officer (Incoming)

Mark Novara has served as our Executive Vice President and Chief Commercial Officer since November 2023. Mr. Novara is an executive with nearly 25 years of general management, strategy, and marketing experience in the medical device, life science, and pharmaceutical industries. Prior to joining Tandem, he served as Senior Advisor in the Medical Technology/Life Science practice at McKinsey & Company since February 2023. Prior to that time, Mr. Novara held executive positions at Becton Dickinson (BD) for more than 11 years, most recently as a Worldwide Vice President/General Manager in the Medication Delivery Solutions business unit from June 2020 to December 2022. He also served as Senior Vice President, Global Strategic Marketing for two of BD’s segments, Medical from May 2018 to June 2020, and Life Sciences from December 2015 to May 2018. Mr. Novara was also a Worldwide Vice President/General Manager in the Diabetes Care business unit from November 2013 to December 2015, and Director of Strategic Marketing and Business Development in the Pharmaceutical Systems business unit from July 2011 to November 2013. He also held leadership positions with Hoffman-La Roche and Sanofi-Aventis. Mr. Novara received a BS in Biology from Villanova University and a Master of Healthcare Management from Columbia University.

Susan Morrison

Executive Vice President and Chief Administrative Officer

Susan Morrison has served as an Executive Vice President since December 2017 and as our Chief Administrative Officer since September 2013, and is responsible for the Company’s investor relations, corporate communications, program management, human resources and facilities functions. Prior to that time she served in successive leadership positions for our Company since November 2007, including Vice President, Human Resources, Corporate and Investor Relations and Director, Corporate and Investor Relations. Prior to joining our Company, Ms. Morrison held various positions in Corporate and Investor Relations at Biosite from August 2003 through November 2007. Ms. Morrison holds a B.A. in Public Relations from Western Michigan University.

Jordan Pinsker, MD

Chief Medical Officer

Dr. Jordan Pinsker has served as our Chief Medical Officer since November 2023 after joining the Company as Vice President and Medical Director in April 2021. He is a leading pediatric endocrinologist and prominent thought leader in artificial pancreas research. Dr. Pinsker joined Tandem from Sansum Diabetes Research Institute in Santa Barbara, California, where he served as the Director of Artificial Pancreas Technology since 2018. In his role at Sansum, he was a lead investigator in numerous clinical trials on automated insulin delivery systems, including Basal-IQ technology and Control-IQ technology. Prior to this, he was Chief of Pediatric Endocrinology at Tripler Army Medical Center in Hawaii. Dr. Pinsker served as a physician in the United States Army in both Active Duty and in the California Army National Guard for more than 20 years. He completed a combined seven-year BS/MD program with Union College and Albany Medical College in New York. Dr. Pinsker is board certified in Clinical Informatics, Pediatric Endocrinology, and General Pediatrics. You can read about many of his studies on his Google Scholar page.

Libba Sapitsky

Senior Vice President, Customer Care

Libba Sapitsky joined us as Senior Vice President, Customer Care in November 2021. Ms. Sapitsky brings more than 30 years of experience in global life sciences and consumer care. Prior to joining Tandem, she served as Vice President of Customer Service and Operations at CVS Health. In her role at CVS, Ms. Sapitsky was a leader of member contact center operations, customer experience, client support, continuous improvement and work force management. Prior to this, she served as Senior Vice President of Customer Service at Siemens Healthineers where she led a dispersed team supporting hospitals and practitioners with contact center operations, field services, customer education and operational effectiveness. Before that, she was a Senior Partner at Kingsley Gate, a global executive consultative search firm with a focus on life sciences, technology and financial services. Ms. Sapitsky also has been a leader in global human resources, operations, automation support, implementation, customer experience, managed services and business development. Ms. Sapitsky holds a BA in English from The University of Texas at Austin.

Leigh Vosseller

Executive Vice President and Chief Financial Officer

Leigh Vosseller has served as our Executive Vice President, Chief Financial Officer, and Treasurer since June 2018, and served as Senior Vice President, Chief Financial Officer and Treasurer from January 2018 to May 2018. Ms. Vosseller is our principal financial and accounting officer. She joined us as Vice President of Finance in 2013 and was promoted to Senior Vice President of Finance in August 2017. Prior to that time, she served as Vice President and Chief Financial Officer at Genoptix, beginning in 2011, after initially joining Genoptix in 2008. Prior to that she held a senior finance position at Biosite where she played a key role in developing the financial and administrative infrastructure for international expansion. Since January 2021, Ms. Vosseller has served as a director and chair of the finance committee of Girls Inc. of San Diego County, a non-profit organization that provides STEM-focused, research-based programming to underserved girls in the community. Ms. Vosseller is a certified public accountant (inactive) and holds a B.S. in Accounting from Missouri State University.

Shannon Hansen

Chief Legal, Privacy & Compliance Officer; Secretary

Shannon Hansen was appointed Chief Legal, Privacy and Compliance Officer; Secretary in August 2023. From January 2022 to July 2023, she served as Senior Vice President, General Counsel, Chief Compliance Officer, Chief Privacy Officer and Secretary. Before joining our Company, Ms. Hansen served as General Counsel, Corporate Secretary and Chief Privacy Officer at Alto Pharmacy from April 2020 to September 2021, where she oversaw the development of the legal, privacy and compliance functions. Before her role at Alto Pharmacy, she held various leadership roles at Abbott, including Division Vice President & Associate General Counsel, Patents from June 2017 to February 2020, Division Vice President and Associate General Counsel for the Diabetes, Vascular and Structural Heart divisions from June 2015 to June 2017, as well as other leadership roles for the Diabetes Division from May 2009 to May 2015. In August 2021, Ms. Hansen began serving as an Independent External Audit and Supervisory Board Member for PHC Holdings Corporation. Earlier in her career, she served as a partner at Kirkland & Ellis LLP, and worked in the Solicitor’s Office at the United States Patent and Trademark Office. Ms. Hansen holds a B.S. in Chemical Engineering from Carnegie Mellon University, and a J.D. from Stanford Law School.

Board of Directors

Board of Directors

Rebecca Robertson

Chair
Ms. Robertson has served as Chair of our board of directors since March 2023, and as a member of our board of directors since January 2019. Ms. Robertson is a founder and General Partner at Versant Ventures where she has specialized in investing in the areas of medical devices and diagnostics since 1999. In addition, through Longridge Business Advisors, she has provided business advisory services and board services since April 2017. Prior to Versant, she served as Senior Vice President at Chiron Diagnostics, a division of Chiron Corporation, where she had responsibility for the critical care business unit in addition to leading the division’s business development efforts. Prior to joining Chiron, Ms. Robertson was a co-founder and Vice President at Egis, a consumer products company, and held senior management positions in operations and finance at Lifescan, a Johnson & Johnson Company. Ms. Robertson holds a B.S. in Chemical Engineering from Cornell University.

Dick Allen

Director
Mr. Allen has served as a member of our board of directors since July 2007. He previously served as Lead Independent Director from March 2019 to February 2023, and as Chair of our board of directors from August 2007 to January 2013 and from January 2016 to February 2019. Mr. Allen is directly engaged in the diabetes community through his personal involvement with JDRF, a nonprofit diabetes research organization, and the Mary & Dick Allen Diabetes Center at Hoag Memorial Hospital Presbyterian. Mr. Allen served as a member of the International Board of Directors of JDRF from July 2008 to June 2014, and as its Chair from July 2012 to June 2014. Mr. Allen has more than 50 years of experience in the health care industry and was previously the President of DIMA Ventures, Inc., a private investment firm providing seed capital and board-level support for start-up companies in the healthcare field. He was a co-founder and Vice President of Caremark, Inc., a home infusion therapy company later acquired by Baxter International. He was also a co-founder and director of Pyxis Corporation, later acquired by Cardinal Health, Inc. Mr. Allen received a B.S. (cum laude) in Industrial Administration from Yale University and an M.B.A. from Stanford University Graduate School of Business where he served on the faculty as a Lecturer in Strategic Management for 13 years.

Kim Blickenstaff

Director
Mr. Blickenstaff has served as a member of our board of directors since September 2007. From March 2020 to February 2023 he served as Chair of our board of directors, after holding the position of Executive Chair since March 2019. Prior to serving as Executive Chair, Mr. Blickenstaff served as our President and Chief Executive Officer from September 2007 to March 2019. He has been a member of our board of directors since September 2007. Prior to joining us, Mr. Blickenstaff served as Chair and Chief Executive Officer of Biosite Incorporated, a provider of medical diagnostic products, from 1988 until its acquisition by Inverness Medical Innovations, Inc. in June 2007. Mr. Blickenstaff previously served as a director of Medivation, Inc., a biotechnology company, from 2005 to 2016, until its acquisition by Pfizer, and as a director of DexCom, Inc. (Nasdaq: DXCM), a provider of continuous glucose monitoring systems, from June 2001 to September 2007. Mr. Blickenstaff serves as a director and member of the compensation and audit committees of Nuvation Bio Inc. (NYSE: NUVB), an oncology biopharmaceutical therapy company. Mr. Blickenstaff was formerly a certified public accountant and has more than 20 years of experience overseeing the preparation of financial statements. He holds a B.A. in Political Science from Loyola University, Chicago, and an M.B.A. from the Graduate School of Business, Loyola University, Chicago.

Myoung Cha

Director
Mr. Cha has served on our board of directors since June 2022. He has more than 17 years of global experience across the healthcare value chain. Mr. Cha currently serves as President and Chief Strategy Officer at Carbon Health where he leads the omnichannel care model and the device-enabled home care operations. Prior to joining Carbon Health in June 2021, he served as Head of Health Strategic Initiatives at Apple from August 2015 to May 2021 where he developed and led product initiatives and global strategic partnerships. Earlier in his career, Mr. Cha was a Principal and Co-Leader of the West Coast Strategy and Corporate Finance Practice as well as Co-Leader of the Healthcare Investor Practice at McKinsey & Company. Mr. Cha holds a JD from Harvard Law School, an MBA from Harvard Business School and an AB in Biochemical Sciences from Harvard College.

Peyton Howell

Director
Ms. Howell joined our board of directors in August 2020. Ms. Howell has more than 25 years of extensive reimbursement, health insurance, and patient access experience across a broad range of disease states in the hospital, physician, pharmacy and home care settings. Ms. Howell is currently the Chief Operating and Growth Officer at Parexel International, a leading global clinical research organization servicing the life sciences industry. Prior to joining Parexel in May 2018, Ms. Howell held a wide range of senior leadership positions at AmerisourceBergen, including leading Global Sourcing and Manufacturer Relations and advancing specialty and biotech products and solutions for physicians, health systems and specialty pharmacies. She was a founder and President of Lash Group, a patient support services company, and an early pioneer of programs to support patient access, reimbursement, and adherence to new therapies including services related to diabetes, such as patient assistance and reimbursement support for continuous glucose monitors. Ms. Howell is a recognized national speaker on health policy, patient access and reimbursement issues. She has served as Director of the AmerisourceBergen Foundation, the National Association of Chain Drug Stores Foundation, and the Healthcare Distribution Alliance Foundation. Ms. Howell received a B.A. in Speech Communication from the University of Illinois at Urbana-Champaign and a Master’s of Health Administration from The Ohio State University.

Joao Malagueira

Director
Mr. Malagueira has served on our board of directors since June 2022. He brings more than 25 years of experience in diabetes, medical devices and diagnostics solutions businesses with global corporations. Mr. Malagueira is currently Vice President for three divisions at Hologic and responsible for the entire portfolio in the EMEA. Prior to starting this role in January 2019, he served as International Vice President, for EMEA and Canada, for the Hologic Diagnostics Solutions division, from June 2015 to December 2018. He possesses extensive experience and proven success of go-to-market models and strategies in Europe, Africa, CIS, and the Middle East. Prior to Hologic, Mr. Malagueira enjoyed more than 15 years at Johnson & Johnson, in commercial leading roles across EMEA, where he led successful turnarounds and market share growth of the diabetes solutions businesses, LifeScan and Animas. Mr. Malagueira holds an MBA and an Advanced Degree in Marketing from Catolica Lisbon School of Business and Economics. He holds a MS in Pharmaceutical Sciences and Clinical Analysis from University of Lisbon.

Kathleen McGroddy-Goetz

Director
Dr. McGroddy-Goetz has served on our board of directors since June 2020. She has more than 25 years of experience leading global teams across business development, strategy, research and development, and product management. She has commercialized pioneering technologies spanning from microelectronics through cloud, advanced data analytics, artificial intelligence, hardware, software, and middleware with an emphasis on healthcare and life sciences applications. From October 2018 through June 2021, Dr. McGroddy-Goetz served as the Global Head of Strategic Partnerships at Medidata Solutions, a Dassault Systemès Company, where she also concurrently held other strategy, alliances and marketing executive roles. Previously, she held various leadership positions at IBM beginning in 1992, and most recently was Vice President, Strategy and Innovation, IBM Watson Health. Dr. McGroddy-Goetz received a BS in Physics from SUNY Binghamton and a PhD in Molecular Biophysics from Cornell University.

John Sheridan

President and Chief Executive Officer

Mr. Sheridan has served on our board of directors since June 2019 and as our President and Chief Executive Officer since March 2019. Prior to that, Mr. Sheridan served as our Executive Vice President and Chief Operating Officer since April 2013. Prior to joining us, Mr. Sheridan served as Chief Operating Officer of Rapiscan Systems, Inc., a provider of security equipment and systems, from March 2012 to February 2013. Mr. Sheridan served as Executive Vice President of Research and Development and Operations for Volcano Corporation, a medical technology company, from November 2004 to March 2010. From May 2002 to May 2004, Mr. Sheridan served as Executive Vice President of Operations at CardioNet, Inc., a medical technology company, now operating as BioTelemetry, Inc. (Nasdaq: BEAT). From March 1998 to May 2002, he served as Vice President of Operations at Digirad Corporation, a medical imaging company. Mr. Sheridan serves as a director of Acutus Medical, Inc. (Nasdaq: AFIB), an arrhythmia management company. Mr. Sheridan holds a BS in Chemistry from the University of West Florida and an MBA from Boston University.

Rajwant “Raj”  Sodhi

Director

Mr. Sodhi has served on our board of directors since January 2021. He has more than 25 years of experience in global informatics, software service technology and ecommerce business solutions, across the healthcare, financial, and telecom industries. Previously he served as the President of ResMed’s software as a service (SaaS) business from July 2017 to August 2021 and as President of Healthcare Informatics (HI) leading the development of ResMed’s HI solutions and ResMed itself to its current standing as a global digital health leader, with an expanding portfolio of device- and SaaS-based offerings. He joined ResMed in 2012 through the acquisition of Umbian Inc. of which he was co-founder and President. Before ResMed and Umbian, Mr. Sodhi worked in the financial services industry, designing, developing and managing SaaS solutions. He was Senior Vice President of Business Development and Chief Technology Officer for Skipjack Financial Services from 2005 to 2009, and co-founder and Chief Technology Officer of TransActive Ecommerce Solutions from 2000 to 2005. Mr. Sodhi is on the board of directors of Forefront Dermatology, EyeCare Partners and NovaResp Technologies. Mr. Sodhi holds an M.B.A. and a B.S. in Mathematics and Statistics from Dalhousie University in Halifax, Nova Scotia.

Christopher Twomey

Director

Mr. Twomey has served on our board of directors since July 2013. Mr. Twomey has served as a director and chair of the audit committee of Bionano Genomics (Nasdaq: BNGO), a life sciences genome analysis instrumentation company since July 2018. From March 1990 until his retirement in 2007, Mr. Twomey held various positions with Biosite, most recently serving as Senior Vice President, Finance and Chief Financial Officer. From 1981 to 1990, Mr. Twomey worked for Ernst & Young LLP, where he served as an Audit Manager. He previously served as a director and chair of the audit committee for public companies, such as Senomyx and Cadence Pharmaceuticals, prior to their acquisitions. Mr. Twomey holds a B.A. in Business Economics from the University of California, Santa Barbara.